Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
CPRXCatalyst Pharmaceuticals(CPRX) Newsfilter·2024-08-08 04:11

Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of 122.7Million,Representinga23.2122.7 Million, Representing a 23.2% YoY Increase FIRDAPSE® Q2 2024 Net Product Revenues of 77.4 Million, Reflecting Strong Organic 19.2% YoY Growth AGAMREE® Q2 2024 Net Product Revenues of 8.7MillionDemonstratesaStrongStarttoU.S.CommercializationFYCOMPA®Q22024NetProductRevenuesof8.7 Million Demonstrates a Strong Start to U.S. Commercialization FYCOMPA® Q2 2024 Net Product Revenues of 36.5 Million, Representing a 5.7% Y ...